daratumumab,talquetamab,teclistamab
genmab,janssen
['mmsm', 'talquetamab', 'teclistamab']
is it time to redirectt myeloma? combining teclistamab and talquetamab is feasible but crs and infections still common as with monotherapies. efficacy is very impressive with orr over 90%!! #asco23 #mmsm #mediq23asco 
Hematologist, Myeloma Expert, Communication Enthusiast. Professor at TGen/City of Hope and Chief Medical Officer of the International Myeloma Foundation